Bristol Myers Squibb and zaiding pharmaceutical sign the relevant license agreement of blineb

Source: Ding Xiangyuan, March 26, 2015 (March 23, 2015, Shanghai News), Bristol Myers Squibb (NYSE Code: BMY) and China's leading innovative pharmaceutical company Zai Lab ）Today, we jointly announced that the two sides have signed an agreement: in the Greater China region, including Hong Kong and Macao, zaiding pharmaceutical will have the exclusive right to develop, produce and promote brivanib Blinib is an oral kinase inhibitor, which is mainly used in the treatment of HCC and other solid tumors Now it is in the global phase III clinical trials Zaiding pharmaceutical will be responsible for the development, production and commercial promotion of brineb in China Bristol Myers Squibb will be eligible to receive milestone payments for different stages of development and a share of its approved commercial sales ladder Bristol Myers Squibb also has the option to work with zaiding Pharmaceutical Co., Ltd to promote and share the commercial profits of brineb in China Bristol Myers Squibb reserves all development and commercial rights of the brineb outside China The remaining terms are not disclosed "HCC is the most common type of primary liver cancer Generally speaking, patients diagnosed as intermediate stage HCC can only survive for 20 months," said Karl lintel, President of Bristol Myers Squibb China We are very pleased to cooperate with zaiding pharmaceutical to further develop as a treatment scheme in Chinese patients with HCC Early clinical trials have shown that in patients with advanced HCC who do not respond to other therapies, it may delay the progression of the disease " "We are very excited about this cooperation," said Samantha Du, founder and CEO of zaiding pharmaceutical Brinib has been tested in a number of global phase III trials, involving many Chinese patients with HCC In Chinese patients with HCC, encouraging data were observed in an acceptable range of safety More than half of the world's new liver cancer patients come from China, with 400000 new cases and 371000 deaths in 2012 Based on the preliminary analysis of a large number of three-phase clinical data, it is expected that brinib will provide a new treatment option for patients with HCC in China " About HCC, HCC is the most common type of liver cancer Most HCC is secondary to viral hepatitis (hepatitis B or C) or cirrhosis Although HCC is a relatively uncommon cancer in developed countries, it has become the third most lethal cancer worldwide, with more than 500000 patients The incidence rate of HCV is the highest in Asia, and the high incidence of HBV and HCV has increased the high incidence of chronic liver disease and hepatocellular carcinoma About Bristol Myers Squibb, a global biopharmaceutical enterprise with the mission of "developing and providing innovative drugs to help patients overcome serious diseases" The company has R & D and commercial operation base in China, and its listed drugs are used to treat cancer, cardiovascular disease, diabetes, hepatitis B, as well as over-the-counter drugs such as vitamins and analgesics In addition, the company operates as a joint venture with Shanghai Pharmaceutical Group and China Pharmaceutical Foreign Trade Company in China, which is known as Sino US Shanghai Squibb Pharmaceutical Co., Ltd or sass for short For more information, please visit Bristol Myers Squibb global official website www.bms.com About zaiding pharmaceutical zaiding Pharmaceutical Co., Ltd is a leading innovative pharmaceutical development company focusing on solving the unmet medical needs for patients all over the world, headquartered in Shanghai The company is building a strong R & D portfolio of treatment projects aimed at changing patients' lives, based on the Chinese market, and taking into account global patients Zaiding pharmaceutical has a world-class management team with rich experience in the field of global pharmaceutical and biotechnology institutions This team has outstanding successful experience - including successfully carrying out clinical trials of five candidate new drugs in China, trying new registration channels, obtaining the approval of registration regulatory authorities in the shortest time, carrying out a number of pilot new drug clinical trials in the United States, and introducing the new drugs discovered in China into the global phase III clinical trials Zaiding pharmaceutical focuses on innovation and creation with the spirit of excellence and team cooperation, and is committed to becoming a leading enterprise focusing on innovative drug research and development in the world